Feelnor(Trimetazidine Dihydrochloride)

Therapeutic Group: Cardiovascular


Feelnor 35 MR tablet: Each modified release tablet contains Trimetazidine Dihydrochloride BP 35 mg.


Feelnor (Trimetazidine) is a unique antianginal and anti-ischaemic agent that display anti-ischaemic effects without inducing haemodynamic changes and improves the status of the ischaemic myocardium.The drug exerts its antianginal effects through a direct cytoprotective action on the myocardium, thereby avoiding the side-effects of impaired left ventricular function, excessive peripheral vasodilation and other disadvantages associated with the use of comparator antianginal agents


Feelnor (Trimetazidine) is indicated for-

* Ischaemic heart disease (angina pectoris, sequelae of infarction).

Dosage & Administration

One 20 mg tablet thrice daily after meals. No dosage adjustments are required in patients with impaired renal and hepatic function.
One 35 mg MR tablet twice daily at mealtimes in the morning and evening.

Side Effects

Feelnor (Trimetazidine) is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.


Safety and efficacy in children have not been established with Trimetazidine.

Use in Pregnancy & Lactation

Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.
Nursing Mothers: There is no information on the secretion of Trimetazidine into breast milk. However, breast feeding should be discontinued if the use of Trimetazidine is considered essential.

Drug Interaction

No drug interactions have so far been reported. In particular, no interactions of Trimetazidine with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis have been reported.

Commercial Pack

Feelnor 35 MR: Each box contains 3 blister strips of 10 tablets.